Multicell Technologies (OTCBB:MCET) rockt die Bude

 

 

 

...hätte ich kaum für möglich gehalten ...dass es auf 0,0028 runter geht  

 

 

http://www.otcmarkets.com/stock/MCET/quote  

http://www.otcmarkets.com/stock/MCET/news  

 

 

Gestern wurden in den USA beinahe 20 % aller Aktien von MCET gehandelt, entweder ist das eine bevorstehende Übernahme, oder es wird ein neuer Zock eingeleitet, bin sehr gespannt, auf diesen Moment warte ich schon lange.

bayerber  

 

kurz nach Handelsbeginn, ist der Kuurs an der Nasdaq bereits um 80% gestiegen

http://www.ariva.de/news/...for-the-Treatment-of-Liver-Cancer-4969178

während ich das schrieb ist der kurs bereits um 110% gestiegen

bayerber  

aber sieht ja nicht so aus!

Immerhin 40% gemacht Gestern!  

Aussichten für Heute:

Overall Average: 96% Strong Buy
Support & Resistance More
2nd Resistance Point 0.0026
1st Resistance Point 0.0024
Last Price   0.0021
1st Support Level 0.0017
2nd Support Level 0.0012
 

http://finance.yahoo.com/news/...gies-granted-u-patent-125100287.html  

Multicell Technologies awarded patent for cancer, hepatitis-fighting platform


By Elizabeth W. Lorenz
PBN Staff Writer

9/3/14


WOONSOCKET – MultiCell Technologies Inc. has been issued a U.S. patent for drug compositions and platform technologies, which are designed treat virus infections and cancer.

The patent seeks to address what the company calls an unmet medical need. The therapeutics will be used to treat hepatitis B and hepatitis C, as well as hepatocellular carcinoma, which is one of the leading causes of cancer deaths worldwide and the fourth most common form of liver cancer. According to the National Cancer Institute, there are more than 1 million cases of hepatocellular carcinoma worldwide and only 16 percent of patients diagnosed with primary liver cancer live longer than five years.

After studying mouse cancer models, MultiCell Technologies found that a combination of MCT-465, a noncoding doubled-stranded RNA therapeutic and MCT-475, a recombinant immunoglobulin-peptide therapeutic, were able to stimulate the animal’s immune system to eradicate an engrafted tumor. The drug combination also promoted a protective immunity toward any new tumor variants by producing more cytokine proteins (interferon gamma and interleukin-2). The proteins produced antigen-specific T cells, leaving immunized mice with significantly lower virus levels than those that weren’t.

Aside from finding new anti-tumor immune cells, findings also provided insight about the immune memory in animals.

MultiCell Technologies Inc. is a clinical-stage biopharmaceutical company based in Woonsocket that develops novel therapeutics and discovery tools in order to treat neurological disorders, hepatic disease and cancer.